Vertex Pharmaceuticals Inc

NASDAQ: VRTX
$499.88
+$27.08 (+5.7%)
Closing Price on November 5, 2024

VRTX Articles

The top analyst upgrades, downgrades and other research calls from Friday include AK Steel, Altice USA, Biogen, Caterpillar, Gilead Sciences and Oracle.
The top analyst upgrades, downgrades and other research calls from Friday include Analog Devices, Camping World, Ciena, Deere, RSP Permian, Ulta Beauty and Yum China.
In Wednesday’s session the markets were largely negative with major money center banks leading the charge down, other investment houses were negative as well. Although crude oil pushed much lower,...
Jefferies analysts remain reasonably bullish, and in their top growth picks for the week the firm focuses on some stocks that could be top momentum stories for the second quarter.
The first quarter's top-performing stocks in the S&P 500 index included two pharmaceutical firms, an electricity generator, a video game maker and a media company.
March 29, 2017: The S&P 500 closed higher on the day, up 0.11 % and 2.56 points to 2,361.14. Separately the DJIA closed down 0.20% on the day at 20,659.39, down approximately 42.11 points. The...
Vertex Pharmaceuticals shares were jumping after the firm released results from two Phase 3 studies in the treatment of cystic fibrosis in ages 12 and older.
A few biopharma stocks made massive runs on Tuesday morning as the result of clinical trial results and earnings. Although not all of these moves were positive the overall sentiment was positive.
The top analyst upgrades, downgrades and initiations seen on Wednesday include Boeing, Capital One, CenturyLink, Morgan Stanley, NRG Energy and Vertex Pharmaceuticals.
The top analyst upgrades, downgrades and initiations seen on Friday include Adobe Systems, Barclays, Dean Foods, Netflix, Simon Property, Snap and Vertex Pharmaceuticals.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Mobileye, Occidental Petroleum, Oracle, Walt Disney, Wal-Mart.
Markets may be slowing down and taking a step back after hitting new highs in what has been known as the Trump rally. Still, a few stocks in the health care sector were are absolutely screaming...
A recent research report from the biotech team at Baird offers their top picks for 2017. While hardly pounding the table, they are cautiously optimistic on the industry.
Needless to say, the past two years have been rough on biotech. The question for investors is which of the stocks hold the best potential in 2017.
In a new research report, the biotech team at RBC reveal their top picks for 2017, and while hardly pounding the table, they are cautiously optimistic.